-+ 0.00%
-+ 0.00%
-+ 0.00%

TD Cowen Maintains Buy on Biogen, Raises Price Target to $215

Benzinga·02/09/2026 16:21:21
Listen to the news
TD Cowen analyst Phil Nadeau maintains Biogen (NASDAQ:BIIB) with a Buy and raises the price target from $175 to $215.